PCSK9 and colorectal carcinoma: [148] used clinically approved PCSK9‐neutralizing antibodies (Evolocumab) to inhibit PCSK9 in CRC liver metastases (CRLC), which led to the downregulation of runt‐related transcription factor‐1 (RUNX1) expression in CRLC cells.